Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 17/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piboserod SCHEMBL467339 | 0.85 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| Piboserod SCHEMBL30234609 | 0.85 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7394362 | 0.84 | HTR4 (0.52) | HTR4 | |
| Piboserod SCHEMBL2228911 | 0.84 | HTR4 (0.98) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7974652 | 0.83 | HTR4 (0.75) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7976735 | 0.77 | HTR4 (0.65) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8286732 | 0.75 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7333331 | 0.75 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8287824 | 0.75 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7365338 | 0.74 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031751-A1 | (+/-)-n-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro-4 -hydroxy-2h-(1,3)oxazino(3,2-alpha)indole-10-carboxamide as seretonin receptor antagonist; gastrointestinal, cardiovacular and central nervous system disorders | SMITHKLINE BEECHAM P.L.C. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031751-A1 | (+/-)-n-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro-4 -hydroxy-2h-(1,3)oxazino(3,2-alpha)indole-10-carboxamide as seretonin receptor antagonist; gastrointestinal, cardiovacular and central nervous system disorders | HTR5A, HTR3A, HTR4 | HTR4 3/4885CHRM2 283/4885ADRA2B 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.